Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF
VS-041, a Novel, First-in-Class, Narrow-spectrum Matrix Metalloproteinase Inhibitor Targets the Underlying Extracellular Matrix Pathology Driving Myocardial Fibrosis and Stiffening ENCINITAS, Calif., and WROCLAW, Poland, June 8, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical...
VS-041, a Novel, First-in-Class, Narrow-spectrum Matrix Metalloproteinase Inhibitor Targets the Underlying Extracellular Matrix Pathology Driving Myocardial Fibrosis and Stiffening ENCINITAS, Calif., and WROCLAW, Poland, June 8, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.